In Vivo Podcasts https://insights.citeline.com/in-vivo/ en All rights reserved The In Vivo Podcast, hosted by David Wild and Anabel Costa-Ferreira, explores the trends, innovations and strategies shaping global life sciences. Designed for biotech and pharmaceutical professionals, episodes feature journalists and industry leaders analyzing emerging technologies, R&D and market forces. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. https://megaphone.imgix.net/podcasts/9d24c7f8-31a9-11f1-b3f1-bbecd499d0a5/image/b73322cc907b245e47e46e7354a8ccff.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress In Vivo Podcasts https://insights.citeline.com/in-vivo/ episodic Norstella The In Vivo Podcast, hosted by David Wild and Anabel Costa-Ferreira, explores the trends, innovations and strategies shaping global life sciences. Designed for biotech and pharmaceutical professionals, episodes feature journalists and industry leaders analyzing emerging technologies, R&D and market forces. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. The In Vivo Podcast, hosted by David Wild and Anabel Costa-Ferreira, explores the trends, innovations and strategies shaping global life sciences. Designed for biotech and pharmaceutical professionals, episodes feature journalists and industry leaders analyzing emerging technologies, R&D and market forces. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

]]> Norstella webpubs@citeline.com Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that. Fri, 21 Aug 2026 07:05:00 -0000 full Norstella One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that. One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.

]]> 1969 no In Vivo Trailer Wed, 19 Aug 2026 17:31:00 -0000 trailer Norstella 103 no Strategic Intent: The Rise Of Mid-Cap Dealmakers Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs. Mon, 17 Aug 2026 17:15:00 -0000 full Norstella Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs. Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

]]> 985 no Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices, and explains how Annexon is building two dedicated commercial teams to support both launches. The conversation also covers Annexon’s oral complement inhibitor ANX1502, capital allocation priorities across late-stage and platform programs, and how most-favored-nation (MFN) pricing dynamics are influencing launch sequencing and ex‑US partnering plans. Tue, 11 Aug 2026 09:51:00 -0000 full Norstella On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices, and explains how Annexon is building two dedicated commercial teams to support both launches. The conversation also covers Annexon’s oral complement inhibitor ANX1502, capital allocation priorities across late-stage and platform programs, and how most-favored-nation (MFN) pricing dynamics are influencing launch sequencing and ex‑US partnering plans. On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices, and explains how Annexon is building two dedicated commercial teams to support both launches. The conversation also covers Annexon’s oral complement inhibitor ANX1502, capital allocation priorities across late-stage and platform programs, and how most-favored-nation (MFN) pricing dynamics are influencing launch sequencing and ex‑US partnering plans.

]]> 2015 no Proof of Concept - AI in Drug Discovery In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them. We cover how simulation is used to find and de-risk drug targets, why some AI tools get adopted while others stall, the translational gap between lab results and real patients, and the honest question of where the field is overhyped — and what would count as real proof. Fri, 07 Aug 2026 07:44:00 -0000 full Norstella In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them. We cover how simulation is used to find and de-risk drug targets, why some AI tools get adopted while others stall, the translational gap between lab results and real patients, and the honest question of where the field is overhyped — and what would count as real proof. In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them.

We cover how simulation is used to find and de-risk drug targets, why some AI tools get adopted while others stall, the translational gap between lab results and real patients, and the honest question of where the field is overhyped — and what would count as real proof.

]]> 2803 no How ElevateBio Is Betting On Every Gene Editing Modality At Once On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks through ElevateBio's full editing stack: AI-designed large serine recombinases, retrotransposon-based insertion, generative AI-optimized base editors, and an LNP delivery platform that has now shown re-dosing and therapeutically meaningful editing in non-human primates. She also makes the case for epigenetic editing as a potentially underappreciated modality, one that could compete with small molecules in indications where you want potency and specificity without permanently rewriting the genome. And she explains why ElevateBio, with six consecutive years of revenue growth and a 98% manufacturing batch success rate, sees its end-to-end CDMO model as uniquely positioned to turn those tools into medicines partners can actually bring to the clinic. Tue, 21 Jul 2026 07:32:00 -0000 full Norstella On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks through ElevateBio's full editing stack: AI-designed large serine recombinases, retrotransposon-based insertion, generative AI-optimized base editors, and an LNP delivery platform that has now shown re-dosing and therapeutically meaningful editing in non-human primates. She also makes the case for epigenetic editing as a potentially underappreciated modality, one that could compete with small molecules in indications where you want potency and specificity without permanently rewriting the genome. And she explains why ElevateBio, with six consecutive years of revenue growth and a 98% manufacturing batch success rate, sees its end-to-end CDMO model as uniquely positioned to turn those tools into medicines partners can actually bring to the clinic. On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks through ElevateBio's full editing stack: AI-designed large serine recombinases, retrotransposon-based insertion, generative AI-optimized base editors, and an LNP delivery platform that has now shown re-dosing and therapeutically meaningful editing in non-human primates. She also makes the case for epigenetic editing as a potentially underappreciated modality, one that could compete with small molecules in indications where you want potency and specificity without permanently rewriting the genome. And she explains why ElevateBio, with six consecutive years of revenue growth and a 98% manufacturing batch success rate, sees its end-to-end CDMO model as uniquely positioned to turn those tools into medicines partners can actually bring to the clinic.

]]> 1562 no Tonix’s Bet On Monoclonal Prevention Of Lyme Disease Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly. In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a fully human monoclonal antibody targeting OspA on the Lyme-causing bacterium Borrelia burgdorferi. Lederman explains why the unusual biology of OspA makes it better suited to a monoclonal approach than a traditional vaccine, how the antibody works inside the tick's midgut to kill the bacteria and block their migration before they can enter a human host, and what the Phase I data tell us about safety, dosing, and the planned two-dose seasonal regimen. He also discusses the adaptive Phase II field study Tonix is preparing for 2027, the lessons (and the lack of information) from the Valor trial, and the long-term questions around who would use this product, how it would be reimbursed, and whether the health economic case can be made for a seasonal preventive in a disease whose chronic form remains medically and politically contested. Fri, 03 Jul 2026 07:54:00 -0000 full Norstella Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly. In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a fully human monoclonal antibody targeting OspA on the Lyme-causing bacterium Borrelia burgdorferi. Lederman explains why the unusual biology of OspA makes it better suited to a monoclonal approach than a traditional vaccine, how the antibody works inside the tick's midgut to kill the bacteria and block their migration before they can enter a human host, and what the Phase I data tell us about safety, dosing, and the planned two-dose seasonal regimen. He also discusses the adaptive Phase II field study Tonix is preparing for 2027, the lessons (and the lack of information) from the Valor trial, and the long-term questions around who would use this product, how it would be reimbursed, and whether the health economic case can be made for a seasonal preventive in a disease whose chronic form remains medically and politically contested. Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly.


In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a fully human monoclonal antibody targeting OspA on the Lyme-causing bacterium Borrelia burgdorferi. Lederman explains why the unusual biology of OspA makes it better suited to a monoclonal approach than a traditional vaccine, how the antibody works inside the tick's midgut to kill the bacteria and block their migration before they can enter a human host, and what the Phase I data tell us about safety, dosing, and the planned two-dose seasonal regimen. He also discusses the adaptive Phase II field study Tonix is preparing for 2027, the lessons (and the lack of information) from the Valor trial, and the long-term questions around who would use this product, how it would be reimbursed, and whether the health economic case can be made for a seasonal preventive in a disease whose chronic form remains medically and politically contested.

]]> 1690 no The Yescarta Launch Examined This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers. Here are some of Harris Kaplan’s contributed articles for In Vivo: Commercialization 3.0: Achieving New Product Success In Health Care’s New Era Commercialization 3.0: Recognizing And Managing The Human Side Of Change Physician Behavioral Inertia: Innovation’s Greatest Enemy Thu, 18 Jun 2026 07:01:00 -0000 full Norstella This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers. Here are some of Harris Kaplan’s contributed articles for In Vivo: Commercialization 3.0: Achieving New Product Success In Health Care’s New Era Commercialization 3.0: Recognizing And Managing The Human Side Of Change Physician Behavioral Inertia: Innovation’s Greatest Enemy This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers.

Here are some of Harris Kaplan’s contributed articles for In Vivo:

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

Commercialization 3.0: Recognizing And Managing The Human Side Of Change

Physician Behavioral Inertia: Innovation’s Greatest Enemy

]]> 2891 no Philips' Shez Partovi on increasing AI adoption, clinicians' attitudes and the hybrid care model AI, Philips, Healthtech, Future Health Index 2026 Tue, 16 Jun 2026 05:45:00 -0000 full Norstella AI, Philips, Healthtech, Future Health Index 2026 AI, Philips, Healthtech, Future Health Index 2026

]]> 1158 no GATC Health’s Derisq AI, A FICO Score for Drug Development GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back. Mon, 08 Jun 2026 05:41:00 -0000 full Norstella GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back. GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back.

]]> 1188 no Jeremy Levin’s Call to Action to Save American Biotech A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-term capital structures mismatched to drug development timelines, eroding public trust in science and vaccines, and the hollowing out of NIH, FDA, and CDC. He outlines what bold leadership looks like in practice — defending facts, engaging patients, and treating biotech as national infrastructure before it's too late. Tue, 02 Jun 2026 17:14:00 -0000 full Norstella A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-term capital structures mismatched to drug development timelines, eroding public trust in science and vaccines, and the hollowing out of NIH, FDA, and CDC. He outlines what bold leadership looks like in practice — defending facts, engaging patients, and treating biotech as national infrastructure before it's too late. A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-term capital structures mismatched to drug development timelines, eroding public trust in science and vaccines, and the hollowing out of NIH, FDA, and CDC. He outlines what bold leadership looks like in practice — defending facts, engaging patients, and treating biotech as national infrastructure before it's too late.

]]> 2341 no Decoding Cell Stress at Soley Therapeutics Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine. Sat, 30 May 2026 01:47:00 -0000 full Norstella Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine. Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

]]> 1779 no Kurma’s €215m Fund And What It Says About European Funding Environment Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment Thu, 14 May 2026 09:56:00 -0000 full Norstella Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale. Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale.

Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment

]]> 1406 no Podcast: Inside Arcutis with CEO Frank Watanabe Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation. #biotech #dermatology #immunodermatology #pharma #drugdevelopment #leadership Tue, 12 May 2026 14:28:00 -0000 full Norstella Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation. #biotech #dermatology #immunodermatology #pharma #drugdevelopment #leadership Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation. #biotech #dermatology #immunodermatology #pharma #drugdevelopment #leadership

]]> 1602 no